SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Short Candidates
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: George the Greek who wrote (554)6/10/2003 3:35:21 PM
From: tuck  Read Replies (1) of 897
 
George,

My understanding is that VTA is a bit different in that it targets existing vasculature in tumors, rather than trying to prevent its growth as in antiangiogenesis. VTA attempts to starve the tumors blood vessels. The OXGN thread is so dead that SI can't find it anymore, but it is still viewable, if not easily locatable by SI's search engine. It is the repository of some good discussion.

Subject 11430

Cheers, Tuck
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News